Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.81 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22216853 | 0.98 | TAAR1 (0.84) | TAAR1GRIN2BSIGMAR1GRIN1NPC1 | |
| SCHEMBL1240954 | 0.98 | TAAR1 (0.84) | TAAR1GRIN2BSIGMAR1GRIN1NPC1 | |
| SCHEMBL21792273 | 0.98 | TAAR1 (0.84) | TAAR1GRIN2BSIGMAR1GRIN1NPC1 | |
| SCHEMBL25002632 | 0.98 | TAAR1 (0.84) | TAAR1GRIN2BSIGMAR1GRIN1NPC1 | |
| SCHEMBL5332051 | 0.98 | TAAR1 (0.84) | TAAR1GRIN2BSIGMAR1GRIN1NPC1 | |
| SCHEMBL24075499 | 0.98 | TAAR1 (0.84) | TAAR1GRIN2BSIGMAR1GRIN1NPC1 | |
| SCHEMBL3665298 | 0.98 | TAAR1 (0.84) | TAAR1GRIN2BSIGMAR1GRIN1NPC1 | |
| SCHEMBL24767088 | 0.98 | TAAR1 (0.84) | TAAR1GRIN2BSIGMAR1GRIN1NPC1 | |
| SCHEMBL3760581 | 0.96 | TAAR1 (0.75) | TAAR1GRIN2BSIGMAR1GRIN1NPC1 | |
| SCHEMBL662411 | 0.92 | GRIN2B (0.76) | TAAR1GRIN2BSIGMAR1GRIN1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053333-A1 | PREPARATION METHOD OF CRYSTAL STRUCTURE ANALYSIS SAMPLE FOR STRUCTURAL ANALYSIS USING CRYSTAL SPONGE METHOD | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4006024-A1 | HETEROCYCLIC AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-06-01 | — | — | EP | disclosed |
| US-7994326-B2 | For treatment of various forms of neurodegeneration, including that from stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease | NORTHWESTERN UNIVERSITY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2018364-A1 | THERAPEUTIC FLUOROETHYL UREAS | Allergan, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-08 | — | — | US | disclosed |
| WO-2007137029-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| CN-1514831-A | Medicinal composition containing 1,3-thiazine derivative | ��Ұ����ҩ��ʽ���� | 2004-07-21 | — | — | CN | disclosed |
| CN-1387519-A | 2-imino-1, 3-thiazine derivatives | SHIONOGI & CO (JP) | 2002-12-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NOS1, NOS2, NOS3 | TAAR1 1066/4885GRIN2B 65/4885SIGMAR1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.